ArticleClinical epidemiology2025
A Claims-Based Algorithm for Identifying Hidradenitis Suppurativa Severity.
Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Information on severity of hidradenitis suppurativa (HS) is not available in administrative claims databases. Accurately identifying HS severity in claims data is important for identifying treatment effect modification by severity. We sought to develop and validate a claims-based algorithm to identify patients with mild, moderate, or severe HS. Methods: Mass General Brigham (MGB) electronic health records (EHR) were linked to Medicaid claims data in the US from October 2016 through December 2019 to identify 350 patients aged 10 years and older with an ICD-10 diagnosis code for HS (L73.1). Chart review determined HS severity. A multinomial LASSO regression within a 70% training sample determined the most influential claims-based variables out of 30 candidates associated with mild, moderate, or severe HS. This model was used to calculate the positive predictive values (PPVs) for each level of HS within the hold-out testing sample. Results: The study cohort was predominantly female (81%) aged 18-45 years (74%) with 26% White and 21% Black patients. We identified 72 patients with mild/uncertain HS, 173 with moderate HS, and 105 with severe HS. One ICD-10 diagnosis of HS had a PPV of 89%, which was further improved to 100% when also requiring the concurrent use of a systemic medication for HS. The PPV was 20% for mild/uncertain, 54% for moderate and 67% for severe HS. When combining severity into mild/moderate versus severe the PPV was 71%, indicating that among those classified as severe, 71% were truly severe. Conclusion: The claims-based algorithm has a reasonable performance in identifying severe HS but had limitations distinguishing moderate and mild HS. The algorithm performed best at distinguishing severity when combining mild and moderate versus severe HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.